PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go:
20
investment:
Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
3RD ROCK is a sustainable activewear brand that aims to make the best and most ethical climbing clothing in the world. It claims that it has developed a worldwide reputation for making extremely comfortable, better fitting, Made-To-Move garments that perform on the rocks, meet high ethical standards, and transition seamlessly into a user's everyday life. The company has witnessed a 215% growth in the last twelve months despite COVID-19, sold over 65,000 units, and garnered £1.3 million in revenue to date. The company has also acquired knowledge from the Goldman-Sachs accelerator programme. It has recycled over 12,000 plastic bottles into its garments and over 1 tonne of sea waste in its leggings and bra-tops The company will use the investment for range expansion with new innovative product lines, build up its Direct-To-Consumer (DTC) model further, and hire key personnel.
days to go:
Expired
investment:
£393,439
Callaly is the UK’s first female care B-Corp that delivers subscription-based organic cotton period products. The company has invented and patented the 'Tampliner', a combination of an organic cotton tampon with a soft mini-liner for built-in leak protection, with a clean insertion and removal, and no hard plastic applicator. It is multi-patented in 30 countries. The company has developed bespoke robotic machinery to automate production at a UK facility. In a £26 billion global femcare market, Callaly claims that its potential tampliner market would constitute 2% to 4% by 2024. The company has received rave reviews from magazines such as Cosmopolitan and Grazia. Callaly plans to begin sales in Europe in the third quarter of 2020 followed by sales in the US and Asia in 2021.
days to go:
Expired
investment:
£1,704,460
Pointvoucher, born as mobile gaming business, is now emerging into a platform and marketplace that unites users, app developers and brands for mutual benefit, by enabling the time spent in mobile apps to be exchanged for real-life rewards. In three years, the company has gained +530K users, seen 580K voucher redemptions and produced over 10 million games. It aims to offer the best marketplace for mobile gamers and to be the preferred SDK provider for third-party game developers. Pointvoucher has already launched four new mobile games and added +450K registered users. In 2018, its revenue increased by 750% and integrated 259 different voucher partners. Additionally, the company signed a deal with Eagle Eye to ensure delivery of greater quality vouchers going forward. Pointvoucher was also nominated at the London Business Award 2019 in the “Highest Domestic Growth” category, and for the Great British Entrepreneur awards 2018.
days to go:
Expired
investment:
£635,619
An online marketplace offering people to invest in global properties. Wealth Migrate allows investors to diversify their portfolios through a safe and simple platform that uses SMART Investing technology. Investors from 55 countries have performed over 2100 transactions, with each transaction averaging £29.4k and receiving returns ranging from 7% to 12%.
In 2017, over £1.1m of revenue was generated from 846 transactions. Wealth Migrate's main sources of income are derived from equity raising fees, investment management fees and exit fees on the demand side. The company intends to reduce its minimum investment amount to attract more customers to the marketplace.
days to go:
Expired
investment:
£1,980,450
Spotlight Consultations aims to diagnose diseases based on evidence-based questionnaires. The company's Algorithmic Questionnaire (AQ) strives to be a simple 3-5 minute questionnaire, dynamically responsive with each question linked to an actionable care pathway. The company estimates that 10% of global health expenditure per annum is spent on diabetes, which is predicted to rise to $825 billion by 2030. Indirect costs from premature death, disability, and diabetes-related health complications add an additional 35% more to this number. Spotlight intends for its AQ to help reduce expenditure and healthcare burden while improving the quality of care and health outcomes. The company will use the investment to support early revenue generation, team expansion and stimulate Research and Development (R&D) tools to cover more diseases like CVD, IBD, chronic pain, and cancers.
days to go:
Expired
investment:
£69,682
